P a r k i n s o n 's disease (PD) is the most common neurodegenerative movement disorder, affecting about 0.5-5% of the population older than age 65, both in European and nonEuropean populations.
population under study. In most studies the prevalence of dementia associated with PD is 20-40% with an incidence of 2.6-9.5 cases per 100 patient-years of observation. 4, 11, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The recent recognition of Dementia with Lewy bodies (DLB), wherein dementia and parkinsonism may occur within one year of each other and are accompanied by cognitive fluctuations and hallucinations, has both complicated and illuminated our understanding of the role of Lewy body pathology in causing dementia with parkinsonism. Although a number of studies have addressed the epidemiology of Parkinson's dementia (PDD), the epidemiology of DLB is not as clear. 28, 29 
IMPACT ON QUALITY OF LIFE, AUTONOMY AND MORTALITY
The effect of PD on quality of life correlates with progression of symptoms and is most closely related to depression, disability, postural impairment and cognitive impairment. 30, 31 The degree of cognitive impairment affecting executive function in patients with PD is associated with impaired decision making capacity. 32 Moreover, PD is associated with long term care placement in Canada. 33 Independent risk factors for nursing home placement among patients with PD include older age, functional impairment, cognitive impairment and hallucinations. 34, 35 In addition to affecting independence, and despite the availability of effective treatments for PD, PD and parkinsonism are associated with increased mortality. 3 6 -3 9 P a r k i n s o n 's dementia confers an increased risk of mortality regardless of whether the patient is living in the community 40 or in a nursing home. 41 Given the potential impact of cognitive deficits on meaningful clinical outcomes, its early identification in PD and of PDD and related conditions is important for future planning. (Table 2) Several different classification systems are used to diagnose dementia in PD (see Table 2 ). Among these are the criteria of Cummings and Benson, 4 2 International Classification for Disease (ICD)-9, 43 ICD-10, 44 the Diagnostic and Statistical Manual (DSM)-III, 45 DSM-III-R, 46 and the DSM-IV. 47 It is clear from examination of Table 2 that a patient could fulfill the criteria for one diagnostic system yet not another. For example, many patients without functional decline and/or memory impairment might meet Cummings and Benson criteria, but would not meet the DSM criteria. The ICD-9 criteria imply that executive dysfunction and memory impairment are both mandatory for the diagnosis. The ICD-10 criteria are vague with respect to whether memory impairment and functional decline are required. Psychiatric etiologies of cognitive disturbance are not specifically excluded in the Cummings and Benson criteria, but are exclusionary in the DSM systems. The variability in definitions used in research contributes to the wide range of PDD prevalence rates, and the inconsistencies reported between studies examining cognition in PD versus PDD.
DEFINITIONS OF DEMENTIA
It could be argued that none of the above diagnostic systems is adequate with respect to PDD. Functional decline related to cognitive decline, as required by the DSM criteria, is often difficult to discern in the PD population due to motor difficulties. None of the above systems classify subtypes of the disorder. Furthermore, no operational criteria specific to PDD are available. A consensus conference should be held to produce operational guidelines outlining specific systematic research criteria for diagnosing dementia in PD (i.e., akin to the NINCDS-ADRDA Work Group for Alzheimer's disease (AD), 48 and the Consensus guidelines for diagnosis of DLB 49 ).
NE U R O P S Y C H O L O G I C A L DI S T I N C T I O N O F CO RT I C A L V E R S U S SUBCORTICAL DEMENTIA
Dementia in PD is commonly labeled "subcortical", entailing slowing of cognitive and motor skills, poor free recall of information in the context of relatively preserved recognition memory (i.e., suggesting a memory retrieval deficit), executive dysfunction (e.g., loss of cognitive flexibility) and mood disturbance (e.g., depression). 50, 51 Aphasia, apraxia, agnosia and severe amnesia are uncommon. 4 2 This is in contrast to a "cortical" dementia picture (e.g., AD) which involves deficits in language and visuospatial functioning and a memory pattern categorized by impaired learning, and rapid forgetting (i.e., no benefit from recognition trials).
Many neuropsychological studies support this distinction. 52, 53 For example, although both AD and PD patients have impaired learning and recall, PD patients show evidence of a primacy effect with relative sparing of recognition memory on word list tasks, compared to AD patients who show a reduced primacy effect and poor recognition memory. 54 This suggests a retrieval deficit in PD as opposed to a storage deficit in AD, and corresponds to a subcortical (i.e., frontal-subcortical) pattern of memory disruption in PD as opposed to a cortical deficit in AD (i.e., temporal-hippocampal).
The utility of the cortical-subcortical dementia distinction has been questioned as simplistic and inaccurate. In PD, frontalsubcortical circuitry is affected, implicating disruption of both THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES 8 systems. 55 Furthermore, cortical changes occur in PD 56, 57 and in DLB 58 and there is evidence of subcortical in addition to cortical degeneration in A D . 5 9 , 6 0 M o r e o v e r, damage to subcortical structures (e.g., thalamus and basal ganglia) can cause "cortical" symptoms such as aphasia, and visuospatial difficulties have been reported in subcortical dementias. 55 If these limitations are recognized, as a general scheme for differentiating clinical cognitive deficit patterns or behavioral syndromes, the corticalsubcortical distinction can be helpful. 50, 61 The term "frontalsubcortical" has been used increasingly to describe PD and other "subcortical" dementias while the relative contributions of "cortical" and "subcortical" changes remain to be fully elucidated.
PSYCHOMETRIC MEASURES IN PD, PDD AND DLB
Some researchers classify patients as demented or nondemented on the basis of scores on psychometric rating scales or mental status examinations. Cut-off scores of less than 123 on the Mattis Dementia Rating Scale 62 or less than 24 on the Mini Mental State Examination 63 have been used in this manner, and represent performance two standard deviations below the normative mean. These measures do not account for age and education and have several psychometric weaknesses. 64 They are more useful for staging progress/severity rather than for diagnostic classification.
Specific and unique cognitive patterns have been identified for PD, PDD, and DLB by investigators employing comprehensive standardized neuropsychological batteries. Identification of distinct cognitive profiles contrasting PD and PDD supports a subtype model rather than a simple progression model. 65, 66 There has also been a suggestion of distinct neuropsychological profiles based on etiology of PD (e.g., sporadic versus familial). 67 In this small study, patients in both groups (who did not differ with regard to several indicators of disease severity) demonstrated impaired executive functioning, but only those with sporadic PD showed explicit memory recall impairment.
PARKINSON'S DISEASE
P a r k i n s o n 's disease patients without dementia often have impairments on standardized cognitive tests. 6 8 Many studies are limited by low statistical power, however, and this has led to inconsistencies in the literature. 6 9 Other factors contributing to these inconsistencies include differing criteria for ruling out dementia, heterogeneous PD samples, variations in methodologies and measures utilized, differences in duration of illness, and varying degrees of control regarding medication regimens. Generalities from better designed studies are reviewed here.
In PD without dementia, simple verbal attentional skills (e.g., Digit Span) are typically preserved. [70] [71] [72] [73] [74] [75] Mild impairment on visual attention span tasks has been reported by some authors 76 but not others. 73 Working memory is reduced, notably on more complex measures with dual-task properties. 71, 75, 77 Learning efficiency and free recall is generally mildly reduced compared to normal controls 73, [77] [78] [79] although a few studies do not report d e c l i n e s .
8 0 Recognition memory is typically intact 7 2 , 7 8 -8 0 although this may be impaired in patients who are taking antiParkinsonian medication. 69 Long-term (i.e., semantic) memory 65 and remote memory 72 are spared. Psychomotor slowing and increased response latencies are commonly observed 76, 78, 81 and may account for deficits observed on tasks of higher order cognitive processing, which require a certain minimal speed of processing. 82 Some investigators have reported impairments on language measures while others have not. 70, 83, 84 A meta-analysis suggested relative sparing of verbal skills. 72 Some investigators report specific visuospatial declines among PD patients without dementia, 70, 73, 85 but others do not. 78, 85 These differences may, in part, relate to primary decreases in psychomotor speed or motor control, abilities often required on visual (e.g., timed) tasks. Zakzanis and Freedman 72 in their meta-analysis, found visuospatial tasks to be minimally affected. Impairment of executive function is most consistently reported in the literature and is often the earliest detectable area of cognitive decline. This includes performance on problem-solving tasks, such as the Wisconsin Card Sorting Test and the Odd-Man-Out task, that require concept formation, spontaneous generation of efficient strategies, set-shifting and the use of feedback to modify response patterns. 73, 77, 78, 86 
PARKINSON'S DISEASE WITH DEMENTIA
The dementia of PD may exhibit a "frontal-subcortical" pattern with deficits in problem-solving, speed of processing, learning eff i c i e n c y, and recall (with relative sparing of recognition memory). 51 Compared to nondemented PD patients, some studies report that PDD patients perform worse on measures of learning efficiency and long delay free word-list recall but not on recognition trials. 83 Others report that PDD patients perform worse on recognition trials compared to both PD patients and normals. 87 A recent meta-analysis suggested that PDD patients exhibit impairment on recognition measures relative to controls, and that they perform worse than nondemented PD patients. 69 Many studies of PDD patients report relative sparing of recognition memory compared to other types of demented patients (e.g., A l z h e i m e r's patients), yet significantly lower performances compared to normals. 54 Long-term semantic recall is typically spared in PDD 65, 88, 89 as is simple attention span. 90 Parkinson's dementia patients show mild deficits on verbal measures. 72 For example, PDD patients are impaired compared to normals and PD patients on letter, category and verb production (i.e., action word fluency) tasks. 83, 87 In one study, PDD patients performed significantly worse than PD patients on the Boston Naming Test. 83 Zakzanis and Freedman 72 reported that category (i.e., semantic) fluency, WAIS-R Performance IQ, and Purdue Pegboard scores were capable of discriminating PDD patients from normal controls (i.e., less than 5% overlap in test score distributions). Patients with PDD are impaired on problem-solving tasks involving concept formation, hypothesis testing and set-shifting. 8 9 Psychomotor slowing is also evident in PDD and decisionmaking time on choice reaction time tasks is substantially worse compared to nondemented PD patients.
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DEMENTIA WITH LEWY BODIES
Lewy body disease may present as a combined corticalsubcortical picture 6 1 , 9 1 that includes deficits in memory, visuospatial function, language, executive function, attention and psychomotor speed. The neuropsychological DLB literature is marked by small sample sizes and variability in terms of how DLB is defined (e.g., neuropathological evidence of DLB+AD (i.e., Lewy body variant of AD), neuropathologically pure DLB (i.e., without AD), use of DLB clinical criteria only). Visuospatial/visuoconstructional performance (e.g., Block Design, copy tasks, shape detection, fragmented letter tasks, etc.) is disproportionally and more severely impaired than typically observed among AD patients. 9 1 -1 0 0 On the clock drawing/ copying task, patients with DLB do not improve on the copy portion of the task, as do patients with PD and AD. 94, 101 Psychomotor speed is reduced compared with AD patients. 94, 95, 98 Impairment on verbal fluency (FAS, Category) tasks has also been consistently reported. [91] [92] [93] [94] 101 As well, there is consistent evidence of equivalently impaired semantic memory/knowledge accessibility in AD and LBD. 91, 92, 95 Hansen et al 91 and Galasko et al 95 reported equivalent impairment of AD and DLB patients on the Boston Naming Test and Category fluency tasks, yet disproportionate impairment by the DLB group on letter fluency. This is in contrast to the commonly observed AD verbal fluency pattern of letter fluency > category fluency. 102 Lambon et al 93 report similar findings, noting naming and verbal fluency impairments in DLB. Also, whereas the DLB group was equally impaired on the two tasks, this group's letter fluency was significantly inferior to that of the AD group. Calderon et al 92 reported equally impaired naming, category fluency and letter fluency between groups of DLB and AD patients, and a trend toward inferior performance on letter fluency by DLB patients. Patients with DLB are significantly impaired on attentional tasks including Digit Span, vigilance, sustained attention, divided attention, selective attention, and reaction time tasks. 91, 92, 103, 104 There is a suggestion that attentional deficits are more widespread and severe than seen in AD (e.g., see Calderon et al 92 ). Comparison with AD samples with regard to Digit Span has produced inconsistent reports (see Lambon et al 9 3 f o r review). Fluctuating attention/cognition is characteristic of the LBD syndrome. This can be assessed using observational methods amenable to clinical practice. Recent data suggest that cognitive fluctuation may also occur in PDD, blurring the distinction from DLB. 109 Patients with DLB may be better oriented than A D patients. 98, 110 More severe memory loss than normally seen in PD is common, including impairments on recognition memory t a s k s . 9 2 , 9 3 , 9 8 Episodic memory impairment is generally less severe than in AD 92,94,98,100,110 although a few authors report memory impairment equal to that seen in AD. 91, 95 The finding of equally severe memory impairment in LBD and AD groups by Hansen et al 91 and Galasko et al 95 may be related to the fact that their Lewy body groups showed mixed neuropathology (AD+LBD). In neuropathologically pure DLB patients, Salmon et al 94 found significant impairments on all aspects of a verbal learning and recall task (i.e., California Verbal Learning Test), without the typical pattern or severity of losses observed in AD. For example, recognition memory was not exceptionally impaired, and their group did not show an increased propensity for intrusion errors when cued.
Dementia with Lewy bodies patients generally have difficulty in executive function compared to matched controls (e.g., Trails B, Similarities, card sorting tests). 91, 94, 99, 101 Because the initial clinical presentation of DLB can be very similar to AD (with memory complaints and only minimal extrapyramidal signs), referral to a neuropsychologist for detailed assessment may be useful diagnostically.
INCIDENCE STUDIES OF PDD
Incidence studies offer many advantages over cross-sectional prevalence studies including the prospective identification of risk factors for disease and outcomes such as mortality (Table 3) . Because of differential mortality, 39, 40 prevalence studies do not reflect the true impact of dementia in PD. 111 Incidence rates in recent studies range from as low as approximately 2.1 per 100 patient years of observation in an earlier clinic based sample 21 with a mean age of 56 years to as high as 9.5 per 100 patient years in a recent population-based study that had a mean age of 70 years. 26 In general, participants who are older and more cognitively impaired are less likely to participate and more likely to withdraw from studies. 112 Patients referred to clinics may differ from those in population-based studies. For example, movement disorder clinics might be referred younger or more complicated patients. In contrast to PDD there are no current incidence studies of DLB, reflecting the difficulty in separating the onsets of cognitive and motor impairment, and its more recent definition. (Table 3) A case control study of risk factors for PDD identified education (less than high school), motor severity and an older age of onset as predictors. 113 Incidence studies have identified similar factors. Older age, worse motor function, and axial motor impairment are associated with dementia. [24] [25] [26] While global cognitive impairment is associated with dementia risk, specific 114 verbal memory and executive f u n c t i o n . 11 5 One study showed impairment on the Picture Completion subtest of the WAIS-R, raising the possibility that aspects of visuospatial function may be predictive. 23 A study that examined shared risk factors between AD and PDD found that smoking history predicted dementia in PD while head injury, hypertension and diabetes were not associated with PDD. 116 Estrogen use was a protective factor in some studies.
RISK FACTORS FOR PDD
117,118
GENETIC RISKS AND PDD
The role of genetic factors in PDD is supported by the increased risk of dementia (including AD) in family members of patients with PDD. 119, 120 The effect of polymorphisms associated with an increased risk of AD on the risk of dementia in PD is not clear. One recent study, 121 but not the majority, 122, 123 showed an association between the Apolipoprotein E epsilon 4 (Apo E ε4) allele and increased dementia risk in PD. In another, the Apo E e2 allele increased the risk of PDD. 124 Differences between studies might reflect pathological heterogeneity in PDD; for example, PD patients with coexistent AD pathology might have an overrepresentation of the Apo E ε4 allele, 125, 126 but this has not been confirmed. 127 The Apo E ε4 may be a shared risk factor for these disorders. 128, 129 Dipeptidyl-carboxypeptidase 1 was found to be associated with PD with coexistent AD pathology while butyrylcholinesterase and estrogen receptor polymorphisms were not. 130, 131 One study found an association with PDD and estrogen receptor gene polymorphisms in a Japanese population. 1 3 2 Mitochondrial genes have been implicated in both AD and PD. 133 Cases of familial DLB have been described. [134] [135] [136] Studies of DLB generally show an association with Apo E ε4. [137] [138] [139] Other genes associated with AD that have been examined in relation to DLB include polymorphisms in the amyloid precursor protein, 140 a l p h a 2 -m a c r o g l o b u l i n , 1 4 1 presenilin 1, 1 4 2 and alpha-1 antichymotrypsin 143 with no clear association. A gene associated with peripheral dopamine metabolism, CYP2D6, has been associated with DLB in some 144 but not all studies. 145 Agedependent changes in prevalence of alleles, as exemplified by the CYP2D6 allele, might affect results. 146 Mitochondrial genes, 147 and monoamine oxidase polymorphisms, 148 have been examined with conflicting results.
An association between PD and the tau gene, including polymorphisms associated with progressive supranuclear palsy and corticobasal degeneration, has been described in some studies 149, 150 but was not confirmed in a pathologically proven sample 151 and the relationship between tau polymorphism and dementia risk has not been examined. 152 Other loci may be involved in PD. 153 The association between tau mutations and frontotemporal dementia, often with parkinsonism (but without Lewy bodies) makes this an important candidate gene for PDD.
Dementia has been observed in autosomal dominant familial PD. 154, 155 In a study that examined cognitive function in patients with familial PD, deficits were observed among family members, 156 consistent with a study where family members of PD patients showed motor deficits.
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PSYCHOSIS AND PARKINSONISM: PD, PDD, DLB AND THEIR
OVERLAP
Hallucinations are common in PD and are included in the core criteria for DLB. There is debate as to whether or not these constitute two separable disorders. 1 5 8 Dementia with Lewy bodies is defined as a dementia occurring in association with two signs or symptoms among parkinsonism, visual hallucinations and cognitive fluctuations 29 (see Table 4 contrasting PDD and DLB). Patients may have additional manifestations including frequent falls, syncope and additional psychiatric symptoms. 29, [159] [160] [161] Hallucinations and delusions occur in PD, PDD and DLB with increasing frequency, while depression may be equally frequent in each of these disorders. 162, 163 By the original convention, dementia and parkinsonism occur within one year of each other in DLB; however, DLB overlaps pathologically with PD. Recent studies have specified that clinical parkinsonism should have been present for at least two years to assure that PD patients have clear onset of motor signs prior to dementia. 1 6 4 Cognitive fluctuations, thought to be suggestive of DLB, also occur in PD. 109 Pathologic changes of AD, specifically amyloid plaques, may or may not coexist with Lewy bodies that are diffusely distributed throughout the n e o c o r t e x . 1 5 8 , 1 6 5 Patients with PD who develop early hallucinations (within one year of treatment) are likely to have a premorbid psychotic illness or DLB. 166 One key clinical feature in DLB is the presence of dramatic neuroleptic sensitivity to conventional and even some atypical neuroleptics in many patients. 167 The recognition of DLB has allowed more prudent treatment of these patients with specific atypical neuroleptics such as clozapine or quetiapine, agents that are also effective for psychosis in PD. The basis of hallucinations in DLB and PD is not known, but neurochemical heterogeneity 1 6 8 or specific pathological involvement; for example, involvement of the temporal lobe, may be implicated. 169 It has been suggested that REM sleep behavior disorder may be characteristic of Lewy body disorders and other synucleinopathies 170 and that such problems may contribute to hallucinations. 171 A comparison of extrapyramidal signs in DLB and PD, revealed more severe action tremor, axial symptoms and rigidity in DLB. 
Pathology
Although the pathologic basis for PDD remains to be fully delineated, increasing evidence supports the notion that it is heterogeneous and that there may be progressive cortical involvement. 173 Coexistent cortical Alzheimer pathology may contribute to decline in PD. 174 However, such changes are not present to a sufficient degree to warrant a diagnosis of coexistent AD in most cases. 165 Cortical Lewy bodies have been better recognized since the introduction of ubiquitin and alphasynuclein staining. Lewy body densities are significantly associated with cognitive impairment, independent of Alzheimer-type pathology. 175, 176 On the other hand many patients with PD without dementia have diffuse Lewy bodies 177 and the presence of cortical Lewy bodies does not distinguish between DLB and PDD. While parahippocampal Lewy bodies were readily identified in one study, regardless of the designation DLB or PDD, DLB patients had more coexistent plaque pathology. 58 Others have found weak correlations between cortical Lewy bodies and dementia. 178, 179 In addition to Lewy bodies, Lewy neurites are associated with dementia in both DLB and PDD, but can be found in cases of PD without dementia. Moreover, it is evident that alpha-synuclein staining can also be observed in AD and multiple system atrophy. 7, 161 The relationship with AD may be related to interactions between amyloid and alpha-synuclein toxicity that have been observed in model studies.
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Neurochemistry
The dopaminergic deficit in PD has been known since the 1960s. 181 However, additional changes have been noted in c h o l i n e rg i c , 1 8 2 n o r a d r e n e rg i c 1 8 3 and serotonergic systems. 1 8 4 Cholinergic deficits, reflected in decreased frontal choline-acetyl transferase (ChAT) have been associated with cognitive impairment and dementia in PD. 185 Similar changes have been found in DLB patients who died with mild impairment. 186 Nicotinic changes may occur in PDD and DLB. 187 Measures of serotonin turnover (5-HIAA/5-HT) relative to cholinerg i c function (5-HIAA/ChAT) may be associated with hallucinations in DLB, in contrast to decreased serotonin turnover in PD. 188 Cognitive dysfunction has been related to diminished dopamine D1 and D3 receptor binding in PD and PDD. 185, 189 An impaired ability to compensate for loss of dopaminerg i c transmission may be suggested in DLB. 190 The loss of D3 binding, reflecting mesolimbic dopaminergic neurons, might be associated with dopamine non-responsive symptoms.
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Neuroimaging
Deficiencies in [ 1 8 F] fluoro-dihydroxyphenylalanine by positron emssion tomography have been noted in PDD patients in the caudate, ventral striatum and anterior cingulate. 1 9 2 D e m e n t i a with Lewy bodies can be differentiated from AD and PD on the basis of decreased dopamine transporter binding using [ 1 2 3 I ] -b e t ac a r b o m e t h o x y -3 -b e t a -( 4 -i o d o p h e n y l ) -n o r t r o p a n e, a pre-synaptic dopamine transporter marker: both PD and DLB show decreased transporter binding, which may be more severe in DLB, in keeping with the autopsy-based neurochemical studies. Changes in blood flow may correlate with frontal and global cognitive dysfunction in PD patients. [195] [196] [197] Others have not been able to distinguish PDD from AD using [18F] fluorodeoxyglucose positron emission tomography. [198] [199] [200] [201] [202] [203] Decreases in perfusion or glucose metabolism in PDD compared to PD have been shown. 204, 205 Compared with matched AD patients, PDD patients show a greater decrease in occipital glucose metabolism, with sparing of medial temporal metabolism, 206 findings reminiscent of DLB. 207 Cholinergic binding is reduced in PDD as in AD. 208 One study showed that DLB, PD and AD could be distinguished by the pattern blood flow measured by 99mTc hexamethylpropylenamineoxime SPECT: DLB showed greater hypoperfusion compared to PD, except in the frontal and occipital regions, and frontal perfusion was lower in DLB compared to AD. 209 In DLB more occipital hypoperfusion may be evident, 2 1 0 -2 1 2 and temporoparietal hypoperfusion may correlate with cognitive function. 213 In another study, decreased blood flow using 99mTc hexamethylpropylenamineoxime SPECT in LBD did not correlate with cognitive function, but was similar to that seen in AD patients. 214 Structural imaging (e.g., CT, MRI) has been applied to the evaluation of dementia in PD. Atrophy on MRI is associated with cognitive decline in PD. 215, 216 Hippocampal atrophy can be seen in PD with and without dementia, 217 a finding that was not replicated in another study, 218 but shown in a study of older PD patients. 219 Patients with DLB similarly show medial temporal atrophy, 220 but to a lesser degree than in AD. This pattern in DLB, with sparing of medial temporal structures compared to AD, has been confirmed by other investigators. [221] [222] [223] Atrophy in the substantia inominata has likewise been observed in AD and other dementias, including PDD. 224 Patients with DLB have a rate of brain atrophy similar to that observed in A D . 2 2 5 Volumetric change of the basal ganglia or occipital lobe has not been seen in DLB, but white matter changes may be observed. Changes on MR spectroscopy in cortical N-acetyl aspartate/creatine 229 are correlated with cognitive change, and are associated with dementia in PD 87 -findings that offer the potential of a widely available dynamic biomarker for dementia in parkinsonian syndromes. Similarly, MR spectroscopy findings have been reported in DLB. 230 In the future, developments in imaging promise to further advance the development of MRI as a biomarker in neurodegenerative disease as well as a differential diagnostic tool.
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IMPACT OF FUNCTIONAL NEUROSURGERY ON COGNITION
Although a complete review of cognitive consequences of stereotactic surgery for movement disorders is beyond the scope of this article, neuropsychological evaluation is considered a standard part of the presurgical work-up. 232 This process allows for determination of whether the candidate has dementia or cognitive impairment, which increases risk for postoperative cognitive decline. Specific aspects of cognition may be affected by surgery. 233 It is important to establish the person's cognitive capability to understand the decision to have surgery including the risks involved, to provide informed consent and to assess their ability to remain cooperative and alert during the procedure. Evaluation of depression, anxiety and psychiatric disturbance that could interfere with surgery, or be exacerbated by the surgical process, is also important.
EVALUATION AND TREATMENT OF PDD Evaluation
Guidelines for the evaluation of people with dementia in the general population have been published, however it is unclear if these apply to PD patients who develop dementia. 13, [234] [235] [236] Since dementia is part of the natural history of PD, one might argue that blood work and neuroimaging might not be routinely necessary. 237 In the community, even though it is unusual to identify completely reversible causes of dementia, it is more common to identify factors that might contribute to cognitive impairment. 238 The greatest benefit is expected when reversible factors are treated and when patients have mild cognitive impairment. It would, therefore, seem prudent to identify dementia and cognitive impairment as it appears in PD patients and to tailor investigations based on clinical assessment, but not to deny patients an evaluation that might reveal occult contributors to cognitive decline.
Assessment of dementia in the patient with parkinsonism includes a careful history (e.g., focusing on the nature of the deficit, onset i.e., gradual vs. sudden and course, etc.) and examination. A review of systems and medications is important. Mental status evaluation using standardized instruments such as the Mini-Mental State Examination may be helpful, especially if a clear decline is documented. 239 On the other hand the MiniMental State Examination is not sensitive to deficits in executive dysfunction, common in PD. 2 4 0 The development of brief instruments sensitive to frontal dysfunction, such as the Frontal Assessment Battery and other, related instruments 241,242 may partially fill this void. Nevertheless, it remains important to assess various aspects of individual cognitive domains, including memory, visuospatial function, language and praxis in patients with movement disorders in whom cognitive impairment is of concern. Referral to a neuropsychologist may be helpful in patients in whom cognitive dysfunction is of concern.
A psychiatric history addressing psychotic and depressive symptoms is important, given the prevalence of psychosis and depression in PD. 243 Depression can be associated with impaired cognition. 244 Assessment instruments that can be helpful for grading the degree of depressive symptoms are available. These include the Beck, 245 Hamilton, 246 Geriatric 247 and Cornell
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Depression Scales. The physical examination of patients with PDD should focus on the identification of potential medical conditions that might exacerbate cognitive dysfunction, including postural hypotension and illnesses unrelated to PD (e.g., pneumonia, congestive heart failure, malignancy, diabetes). New focal neurological signs may suggest cerebrovascular disease. One should also reevaluate the diagnosis, looking specifically for autonomic dysfunction, gaze abnormalities, dysmetria, pyramidal signs, neuropathy, and gait ataxia. Laboratory testing for occult illness includes complete blood count, glucose, electrolytes, urea, creatinine, liver function tests, thyroid stimulating hormone, and a vitamin B12 level. If there is an acute change, suggesting a delirium, a work-up for infection should be included, along with metabolic studies and other assessments targeted by the history and physical examination. A rapid progression, focal signs, and prominent gait impairment raise the concern of additional intracranial pathology, motivating imaging.
Treatment
Reversible causes should be treated. In particular, medications that might be contributing to cognitive dysfunction should be discontinued. A n t i c h o l i n e rgic medications are important to eliminate because they are associated with cognitive impairment. [249] [250] [251] [252] [253] Psychosis can improve with reduction and elimination of some medications, particularly selegeline, amantadine and dopamine agonists. In some patients levodopa might have to be decreased. It is not as clear whether reducing antiparkinsonian medications improve cognition, but simplification of medication regimens is reasonable if cognitive impairment is identified. Changes in medication should be undertaken with caution due to the possibility of drug withdrawal delirium, as has been observed with amantadine 254, 255 and the risk of inducing neuroleptic malignant syndrome. [256] [257] [258] [259] Currently there are no approved cognition-enhancing drugs for patients with PD. Depression can be treated with counseling and medications. Psychosis that does not reverse with medication changes, or elimination of identifiable triggers can be treated with atypical antipsychotic medications. 260 These include clozapine, quetiapine and olanzapine. Typical neuroleptics predictably worsen parkinsonism. 261 Clozapine is the only agent that has been subject to a double blind placebo-controlled study for psychosis in PD, 262 but must be monitored with weekly or two-weekly blood tests to monitor for agranulocytosis. A placebo-controlled trial that was designed to compare clozapine to olanzapine 2 6 3 revealed worsened motor function with olanzapine. Another study found that olanzapine did not improve psychosis. 264, 265 Similar concerns apply in DLB. 266 Quetiapine is an atypical antipsychotic that appears effective in open label experience, possibly with less (but not without) potential to exacerbate parkinsonism. 267, 268 The propensity for improving psychosis without extrapyramidal effects may relate to the kinetics of drug binding to D2 dopamine receptors, whose blockade leads to parkinsonism. 269 Blockade of serotonergic recepters (5-HT2A) or subtypes of dopaminergic recepters may also be relevant.
Given the profound cholinergic deficits in PD and PDD, c h o l i n e rgic enhancing medications are under evaluation in PDD. Nevertheless there remain concerns regarding the possibility of exacerbating motor symptoms. 2 7 0 , 2 7 1 Aplacebo-controlled trial of rivastigmine, a cholinesterase inhibitor, has demonstrated cognitive and behavioral improvement in DLB. 2 7 2 Open label experience with rivastigmine has been published for patients with PDD and has shown improvement of psychotic symptoms, sleep disturbance and caregiver distress. 2 7 3 , 2 7 4 Improved psychosis has been similarly shown with donepezil. 2 7 5 , 2 7 6 R e c e n t l y, a placebocontrolled crossover study demonstrated significant improvement in PDD patients treated with donepezil. 2 7 7 Open label benefits in cognitive function has also been reported for PDD with d o n e p e z i l 2 7 8 and tacrine. 2 7 9 Medications that directly affect the n i c o t i n e rgic system may have promise in PDD. 
Competency and advance directives
Because of the cognitive declines often noted among PD patients, decision-making competence is sometimes called into question. For example, capacity to consent to medical treatment may be reduced by impaired executive function. Recent research on cognitively impaired PD patients reported impaired consent capacity under four different legal standards, particularly with regard to comprehension of treatment information (including risks and benefits) and the provision of rational/logical reasons for a treatment choice. 32 Furthermore, performance on cognitive tests predicted performance on measures of three of the four legal competence standards. 32 Neuropsychological assessment is often conducted to assist with competency assessment.
Even if the patient is cognitively competent, planning for the future is at issue in any progressive neurological condition. That is, it is important to plan for future health care and personal affairs. It is recommended that individuals prepare personal directive and enduring power of attorney documents at a time when they are cognitively competent, as a safeguard, in case cognitive difficulties progress. These documents vary in nature by jurisdiction. Ty p i c a l l y, however, the personal/advanced directive allows for designation of an agent to make decisions on o n e 's behalf should one become mentally/cognitively incompetent. Information covered includes not only the name of the individual to whom this decision-making power is designated, but also an outline of the individual's health care wishes. The Enduring Power of Attorney also names an agent, but this document is typically concerned only with management of the individual's financial affairs should they become cognitively incompetent. Declaration of incompetence by two health care professionals is typically required for activation of these documents. In most states/provinces, if an individual does not have a personal directive and Enduring Power of Attorney and has lost capacity, guardianship/trusteeship are sought (i.e., person is no longer capable of assigning an agent for a personal directive or power of attorney).
SUMMARY
Cognitive impairment is common in PD and is a major cause of disability. While clinical and psychological risk factors are continuing to be defined, it is likely that imaging and genetic predictors will soon be identified. This will provide insight into the pathophysiology of dementia in addition to predictive potential. Such studies will then need to be coupled with pathological investigations of well-defined, longitudinally assessed, cohorts of patients, as has been done in AD. This approach will allow the border-zone between Lewy body disorders and other age related disorders to be clarified. Clearly the future hope is to develop treatments that can accompany supportive management with the goal of preventing dementia.
